1. Home
  2. DMAC vs AACB Comparison

DMAC vs AACB Comparison

Compare DMAC & AACB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DMAC
  • AACB
  • Stock Information
  • Founded
  • DMAC 2000
  • AACB 2024
  • Country
  • DMAC United States
  • AACB United States
  • Employees
  • DMAC N/A
  • AACB N/A
  • Industry
  • DMAC Biotechnology: Pharmaceutical Preparations
  • AACB
  • Sector
  • DMAC Health Care
  • AACB
  • Exchange
  • DMAC Nasdaq
  • AACB Nasdaq
  • Market Cap
  • DMAC 321.5M
  • AACB 283.7M
  • IPO Year
  • DMAC N/A
  • AACB 2025
  • Fundamental
  • Price
  • DMAC $5.95
  • AACB $10.28
  • Analyst Decision
  • DMAC Strong Buy
  • AACB
  • Analyst Count
  • DMAC 4
  • AACB 0
  • Target Price
  • DMAC $15.50
  • AACB N/A
  • AVG Volume (30 Days)
  • DMAC 315.3K
  • AACB 7.5K
  • Earning Date
  • DMAC 11-12-2025
  • AACB 01-01-0001
  • Dividend Yield
  • DMAC N/A
  • AACB N/A
  • EPS Growth
  • DMAC N/A
  • AACB N/A
  • EPS
  • DMAC N/A
  • AACB N/A
  • Revenue
  • DMAC N/A
  • AACB N/A
  • Revenue This Year
  • DMAC N/A
  • AACB N/A
  • Revenue Next Year
  • DMAC N/A
  • AACB N/A
  • P/E Ratio
  • DMAC N/A
  • AACB N/A
  • Revenue Growth
  • DMAC N/A
  • AACB N/A
  • 52 Week Low
  • DMAC $3.19
  • AACB $9.85
  • 52 Week High
  • DMAC $7.49
  • AACB $10.28
  • Technical
  • Relative Strength Index (RSI)
  • DMAC 42.03
  • AACB N/A
  • Support Level
  • DMAC $5.26
  • AACB N/A
  • Resistance Level
  • DMAC $6.47
  • AACB N/A
  • Average True Range (ATR)
  • DMAC 0.41
  • AACB 0.00
  • MACD
  • DMAC -0.10
  • AACB 0.00
  • Stochastic Oscillator
  • DMAC 36.50
  • AACB 0.00

About DMAC DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.

About AACB Artius II Acquisition Inc. Class A Ordinary Shares

Artius II Acquisition Inc is a blank check company.

Share on Social Networks: